Session » Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

Date: Sunday, November 8, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 633

Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort

9:00AM-11:00AM: Abstract Number: 638

Assessment of Myocardial Abnormalities in Primary Sjögren Syndrome Using a Comprehensive Cardiac Magnetic Resonance Approach

9:00AM-11:00AM: Abstract Number: 642

Assignable Causes for Fatigue in Primary Sjögren’s Syndrome: Data from the UK Primary Sjögren’s Syndrome Registry

9:00AM-11:00AM: Abstract Number: 639

Association Between Insomnia and EULAR Sjögren’s Syndrome Patient-Reported Index in Korean Patients with Primary Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 634

Big Data International Primary Sjögren Syndrome Registry: Baseline Characterization and Diagnostic Approach in 6047 Patients Fulfilling the 2002 AE Criteria

9:00AM-11:00AM: Abstract Number: 630

Can Extraglandular Manifestations Differentiate Primary Sjögren’s Syndrome from Sjögren’s-Systemic Lupus Erythematosus Overlap Syndrome?

9:00AM-11:00AM: Abstract Number: 627

Clinical Subsets and Presenting Features in Primary Sjögren’s Syndrome: Results from a Single Center Inception Cohort Study

9:00AM-11:00AM: Abstract Number: 626

Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study

9:00AM-11:00AM: Abstract Number: 643

Ethnicity of Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 647

Involvement of Peripheral Nervous System in Primary Sjögren Syndrome, a Gessar Analysis

9:00AM-11:00AM: Abstract Number: 632

Isolated Atrioventricular Block of Unknown Origin in the Adult and Autoimmunity: Diagnostic and Therapeutic Considerations Exemplified By Three Anti-Ro/SSA-Associated Cases

9:00AM-11:00AM: Abstract Number: 648

Klinefelter’s Syndrome (47,XXY) Among Men with Sjögren’s Syndrome

9:00AM-11:00AM: Abstract Number: 641

Pain, Xerostomia and Younger Age Are Major Determinants of Fatigue in Korean Primary Sjögren’s Syndrome Patients: A Comprehensive Analysis of a Cohort Study

9:00AM-11:00AM: Abstract Number: 628

Poor Prognosis of Patients with Primary Sjögren Syndrome Who Fulfilled at Diagnosis the Classification Criteria for Concomitant Cryoglobulinemic Vasculitis

9:00AM-11:00AM: Abstract Number: 644

Predicting the Risk for Lymphoma Development in Sjögren’s Syndrome: An Easy to Use Clinical Tool

9:00AM-11:00AM: Abstract Number: 621

Previous Diagnosis of Sjögren’s Syndrome As Rheumatoid Arthritis or Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 637

Repeated B Lymphocyte Depletion Therapy with Rituximab in Sjögren’s Syndrome: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 629

Salivary Gland Ultrasonography As an Useful Tool to Distinguish Patients with Sjögren’s Syndrome at Risk for Non-Hodgkin’s Lymphoma Development

9:00AM-11:00AM: Abstract Number: 635

Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort

9:00AM-11:00AM: Abstract Number: 623

Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity

9:00AM-11:00AM: Abstract Number: 646

Sicca Syndrome in Rheumatoid Arthritis: Is It a Real Sjögren’s?

9:00AM-11:00AM: Abstract Number: 624

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Oral Disease Management: Caries Prevention

9:00AM-11:00AM: Abstract Number: 622

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Dry Eyes

9:00AM-11:00AM: Abstract Number: 625

Sjögren’s Syndrome Foundation Clinical Practice Guidelines for Management of Systemic Disease

9:00AM-11:00AM: Abstract Number: 640

Sjögren’s Syndrome in Male Patients Presents with Higher Autoantibody Levels and More Extraglandular Manifestations

9:00AM-11:00AM: Abstract Number: 645

Subclinical Cardiovascular Involvement in Patients with Primary Sjögren Syndrome

9:00AM-11:00AM: Abstract Number: 631

Usefulness of the Minimally-Invasive Minor Salivary Gland Biopsy in Patients Presenting with Sicca Syndrome: Prospective Evaluation of 200 Patients

9:00AM-11:00AM: Abstract Number: 636

Utility of IgA Anti-Alpha-Fodrin Antibodies in Combination with Rheumatoid Factor and/or Antinuclear Antibodies As Substitute Immunological Criterion for Sjögren’s Syndrome

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].